## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Examiner: Fredman, Jeffrey Norman
Kevin P. BAKER, et al. ( NOV 0 8 2004 )	Art Unit: 1637
Application Serial No. 10/015,	Confirmation No: 9861
Filed: December 12, 2001	Attorney's Docket No. 39780-2830 P1C54
For: SECRETED AND ) TRANSMEMBRANE ) POLYPEPTIDES AND NUCLEIC ) ACIDS ENCODING THE SAME )	Customer No. 35489

EXPRESS MAIL LABEL NO. EL 977 609 574 US

**DATE MAILED: NOVEMBER 8, 2004** 

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

## MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

	Inis sta	tement is not int	ended to represent that a search has been made or that the information				
cited in	the state	ement is, or is co	nsidered to be, material to patentability as defined in §1.56.				
	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):						
		(1) than a c	It is being filed within 3 months of the application filing date and is other continued prosecution application under § 1.53(d) OR				
		(2)	It is being filed within 3 months of entry of a national stage OR				
		(3) merits	It is being filed before the mail date of the first Office Action on the OR				
1/12/2004 1 FC:1806		00000021 081641 180.00 DA	10015387 -1-				

11

			before the mailing of a first Office Action after the filing ed examination under § 1.114.			
	filing d stage as action of	ate of a national application; (2) set forth in §1.491 in an interna	being filed after the latest of: (1) three months beyond the three months beyond the date of entry of the national ational application; or (3) the mailing date of a first Office ling date of the earlier of a final office action under §1.113 then:			
		a certification as specified in §1	.97(e) is provided below; or			
		a fee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.				
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:					
	A.	a certification as specified in §1	.97(e) is completed below; and			
	B.	a petition under 37 C.F.R. §1.9 submitted herewith; and	7(d) requesting consideration of this statement is			
	C.	a fee of \$180.00 as set forth in the payment of other papers file	$\S1.17(i)(1)$ is authorized below, enclosed, or included with ed together with this statement.			
$\boxtimes$	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Attorney's Docket No. 39780-2830 P1C54).					
			Respectfully submitted,			
Dated:	Novem	ber 8, 2004	By: Anna L. Barry, Ph.D. (Reg. No. 51,436)			

HELLER EHRMAN WHITE & MCAULIFFE LLP

275 Middlefield Road

Menlo Park, California 94025-3506

Telephone: (650) 324-7000 Facsimile: (650) 324-0638

INFORMATION ASCLOSURE STATEMENT PAGENTY PTO-1449

ATTY. DOCKET NO.: SERIAL NO.:

39780-2830 P1C54

10/015,387

APPLICANT: Kevin P. BAKER, et al.

FILING DATE: December 12, 2001 | GROUP: 1637

		FILING DATE: December 12, 2001		GROUP: 1037				
	U.	S. PATENT DOCUMENTS						
PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE			
	FOF	REIGN PATENT DOCUMENTS			<u> </u>			
						TRANSLATION		
	52		0200	00002.100	YES NO			
		,						
OTHER DO	OCUMENTS	(Including Author, Title, Date, P	ertinent Pa	ages, Etc.)				
Ahlgren, Ulf, et al., "β-Cell-specific inactivation of the mouse <i>Ipf1/Pdx1</i> gene results in loss of the β-Cell phenotype and maturity onset diabetes", Genes & Development, Vol. 12, pp. 1763-1768, 1998.								
Boj, Sylvia F., et al., "A transcription factor regulatory circuit in differentiated pancreatic cells", PNAS, Vol. 98, No. 25 December 4, 2001.  Eto, Yoko, et al., "Anti-Mitogenic Effects of Sarpogrelate In Cultured Rat Mesangial Cells", Life Sciences, Vol. 60, No. pp PL 193-199, 1997.								
							Kashgarian, Michael, et al., "Mesangium and Glomerular Disease", Laboratory Investigation, Vol. 52, 1985.	
Gohda, Tomohito, et. al., "Dilazep Hydrochloride, an Antiplatelet Drug, Inhibits Lipopolysaccharide-Induced Mouse Mesangial Cell IL-6 Secretion and Proliferation", Kidney & Blood Pressure Research, Vol. 24, pp 33-38, 2001.								
Diabetes, Vol. 50, August 2001.						With Type 2		
						, Vol. 69, No. 4, October 1989.		
Offield, Martin, F., "PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum". Department of Cell Biology", Vol. 122, pp 983-995, 1996.  Ono, Takahiko, et al., "Broad Antiproliferative Effects of Benidipine on Cultured Human Mesangial Cells in Cell Cycle Phases", American Journal of Nephrology", Vol. 22, pp 581-586, 2002.								
				rogressive Glor	neruloscl	erosis",		
		DATE CONSIDERED						
	PATENT NO.  OTHER DO Ahlgren, Ulf, et al., " maturity onset diabet Boj, Sylvia F., et al., December 4, 2001.  Eto, Yoko, et al., "Anpp PL 193-199, 1997 Kashgarian, Michael 1985.  Gohda, Tomohito, et Mesangial Cell IL-6 Leibowitz, Gil, et al. Diabetes, Vol. 50, And Mene, Paolo, et al.  Offield, Martin, F., Department of Cell Ono, Takahiko, et al. Cell Cycle Phases"  Ruef, Christian, et Vol. 38, pp 249-25  Striker, Liliane J., of the control of the contr	PATENT NO. DATE  PATENT NO. DATE  OTHER DOCUMENTS  Ahlgren, Ulf, et al., "β-Cell-specific maturity onset diabetes", Genes & D  Boj, Sylvia F., et al., "A transcription December 4, 2001.  Eto, Yoko, et al., "Anti-Mitogenic Emp PL 193-199, 1997.  Kashgarian, Michael, et al., "Mesang 1985.  Gohda, Tomohito, et. al., "Dilazep Hesangial Cell IL-6 Secretion and Pleibowitz, Gil, et al. "IPF1/PDX1 Diabetes, Vol. 50, August 2001.  Mene, Paolo, et al., "Physiology offield, Martin, F., "PDX-1 is red Department of Cell Biology", Vol. Ono, Takahiko, et al., "Broad An Cell Cycle Phases", American Jo Ruef, Christian, et al., "Interleukit Vol. 38, pp 249-257, 1990.  Striker, Liliane J., et al., "The Co	U.S. PATENT DOCUMENTS  PATENT NO. DATE NAME  FOREIGN PATENT DOCUMENTS  PATENT NO. DATE COUNTRY  OTHER DOCUMENTS (Including Author, Title, Date, PATENT NO. DATE COUNTRY  OTHER DOCUMENTS (Including Author, Title, Date, PATENT NO. DATE COUNTRY  OTHER DOCUMENTS (Including Author, Title, Date, PATENT NO. DATE COUNTRY  OTHER DOCUMENTS (Including Author, Title, Date, PATENT NO. DATE)  Boj, Sylvia F., et al., "β-Cell-specific inactivation of the mouse Ipf1/Pdx1 ge maturity onset diabetes", Genes & Development, Vol. 12, pp. 1763-1768, 1  Boj, Sylvia F., et al., "A transcription factor regulatory circuit in differential December 4, 2001.  Eto, Yoko, et al., "Anti-Mitogenic Effects of Sarpogrelate In Cultured Rate pp PL 193-199, 1997.  Kashgarian, Michael, et al., "Mesangium and Glomerular Disease", Labora 1985.  Gohda, Tomohito, et. al., "Dilazep Hydrochloride, an Antiplatelet Drug, In Mesangial Cell IL-6 Secretion and Proliferation", Kidney & Blood Pressur Leibowitz, Gil, et al. "IPF1/PDX1 Deficiency and β-Cell Dysfunction in Ps. Diabetes, Vol. 50, August 2001.  Mene, Paolo, et al., "Physiology of the Mesangial Cell", Physiologic Offield, Martin, F., "PDX-1 is required for pancreatic outgrowth an Department of Cell Biology", Vol. 122, pp 983-995, 1996.  Ono, Takahiko, et al., "Broad Antiproliferative Effects of Benidipin Cell Cycle Phases", American Journal of Nephrology", Vol. 22, pp Ruef, Christian, et al., "Interleukin 6 is an autocrine growth factor for Vol. 38, pp 249-257, 1990.  Striker, Liliane J., et al., "The Contribution of Glomerular Mesangia Seminars in Nephrology, Vol. 9, No. 4, pp 318-328, December 1986.	PATENT NO. DATE NAME CLASS  FOREIGN PATENT DOCUMENTS  PATENT NO. DATE COUNTRY CLASS  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Part Ahlgren, Ulf, et al., "β-Cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in maturity onset diabetes", Genes & Development, Vol. 12, pp. 1763-1768, 1998.  Boj, Sylvia F., et al., "A transcription factor regulatory circuit in differentiated pancreating December 4, 2001.  Eto, Yoko, et al., "Anti-Mitogenic Effects of Sarpogrelate In Cultured Rat Mesangial Colp PL 193-199, 1997.  Kashgarian, Michael, et al., "Mesangium and Glomerular Disease", Laboratory Investig 1985.  Gohda, Tomohito, et. al., "Dilazep Hydrochloride, an Antiplatelet Drug, Inhibits Lipope Mesangial Cell IL-6 Secretion and Proliferation", Kidney & Blood Pressure Research, Vol. 1909, 1997.  Leibowitz, Gil, et al. "IPF1/PDX1 Deficiency and β-Cell Dysfunction in Psammomys of Diabetes, Vol. 50, August 2001.  Mene, Paolo, et al., "Physiology of the Mesangial Cell", Physiological Reviews Offield, Martin, F., "PDX-1 is required for pancreatic outgrowth and differential Department of Cell Biology", Vol. 122, pp 983-995, 1996.  Ono, Takahiko, et al., "Broad Antiproliferative Effects of Benidipine on Cultur Cell Cycle Phases", American Journal of Nephrology", Vol. 22, pp 581-586, 20 Ruef, Christian, et al., "Interleukin 6 is an autocrine growth factor for mesangia Vol. 38, pp 249-257, 1990.  Striker, Liliane J., et al., "The Contribution of Glomerular Mesangial Cells to P Seminars in Nephrology, Vol. 9, No. 4, pp 318-328, December 1989.	TOTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Ahlgren, Ulf, et al., "β-Cell-specific inactivation of the mouse IpfI/PdxI gene results in loss of the β-Cell maturity onset diabetes", Genes & Development, Vol. 12, pp. 1763-1768, 1998.  Boj, Sylvia F., et al., "A transcription factor regulatory circuit in differentiated pancreatic cells", PNAS, N December 4, 2001.  Etc, Yoko, et al., "Anti-Mitogenic Effects of Sarpogrelate In Cultured Rat Mesangial Cells", Life Science pp PL 193-199, 1997.  Kashgarian, Michael, et al., "Mesangium and Glomerular Disease", Laboratory Investigation, Vol. 52, No. 43, 1998.  Gohda, Tomohito, et. al., "Dilazep Hydrochloride, an Antiplatelet Drug, Inhibits Lipopolysaccharide-Ind Mesangial Cell IL-6 Secretion and Proliferation", Kidney & Blood Pressure Research, Vol. 24, pp 33-38, Leibowitz, Gil, et al. "IPFI/PDX1 Deficiency and β-Cell Dysfunction in Psammomys obesus, and Anima Diabetes, Vol. 50, August 2001.  Mene, Paolo, et al., "Physiology of the Mesangial Cell", Physiological Reviews, Vol. 69, No. 4 Offield, Martin, F., "PDX-1 is required for pancreatic outgrowth and differentiation of the rost Department of Cell Biology", Vol. 122, pp 983-995, 1996.  Ono, Takahiko, et al., "Broad Antiproliferative Effects of Benidipine on Cultured Human Mesc Cell Cycle Phases", American Journal of Nephrology", Vol. 22, pp 581-586, 2002.  Ruef, Christian, et al., "Interleukin 6 is an autocrine growth factor for mesangial Cells", Kidney Vol. 38, pp 249-257, 1990.  Striker, Liliane J., et al., "The Contribution of Glomerular Mesangial Cells to Progressive Glor Seminars in Nephrology, Vol. 9, No. 4, pp 318-328, December 1989.	PATENT NO. DATE NAME CLASS SUBCLASS FILIN  FOREIGN PATENT DOCUMENTS  PATENT NO. DATE COUNTRY CLASS SUBCLASS FILIN  PATENT NO. DATE COUNTRY CLASS SUBCLASS TANA  YES  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  Ahlgren, Ulf, et al., "β-Cell-specific inactivation of the mouse Inf1/Pdx gene results in loss of the β-Cell phenotyp maturity onset diabetes", Genes & Development, Vol. 12, pp. 1763-1768, 1998.  Boj, Sylvia F., et al., "A transcription factor regulatory circuit in differentiated pancreatic cells", PNAS, Vol. 98, N December 4, 2001.  Eto, Yoko, et al., "Anti-Mitogenic Effects of Sarpogrelate In Cultured Rat Mesangial Cells", Life Sciences, Vol. 60 pp PL 193-199, 1997.  Kashgarian, Michael, et al., "Mesangium and Glomerular Disease", Laboratory Investigation, Vol. 52, No. 6, pp 56 1985.  Gohda, Tomohito, et. al., "Dilazep Hydrochloride, an Antiplatelet Drug, Inhibits Lipopolysaccharide-Induced Mou Mesangial Cell IL-6 Secretion and Proliferation", Kidney & Blood Pressure Research, Vol. 24, pp 33-38, 2001.  Leibowitz, Gil, et al. "IPFI/PDX1 Deficiency and β-Cell Dysfunction in Psammomys obesus, and Animal With Ty Diabetes, Vol. 50, August 2001.  Mene, Paolo, et al., "Physiology of the Mesangial Cell", Physiological Reviews, Vol. 69, No. 4, Octobe Offield, Martin, F., "PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duode Department of Cell Biology", Vol. 122, pp 983-995, 1996.  Ono, Takahiko, et al., "Broad Antiproliferative Effects of Benidipine on Cultured Human Mesangial Cell Cycle Phases", American Journal of Nephrology", Vol. 22, pp 581-586, 2002.  Ruef, Christian, et al., "Interleukin 6 is an autocrine growth factor for mesangial cells", Kidney Internat Vol. 38, pp 249-257, 1990.  Striker, Liliane J., et al., "The Contribution of Glomerular Mesangial Cells to Progressive Glomeruloscl Seminars in Nephrology, Vol. 9, No. 4, pp 318-328, December 1989.		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PE CONTROL		ATTY. DOCKET NO.: 39780-2830 P1C54 APPLICANT: Kevin P. BA FILING DATE: December S. PATENT DOCUMENTS NAME	SERIAL NO.: 10/015,387  al.  GROUP: 1637  SUBCLASS FILING DATE					
FOREIGN PATENT DOCUMENTS								
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	Wolf, Gunter, et al. Cultured Murine M Zalzman, Michal, e	, "Angiotensir lesangial Cells t al., "Reversa	(Including Author, Title, Date, In II Stimulates the Proliferation and ", American Journal of Pathology, I of hyperglycemia in mice by using genitor cells", PNAS, Vol. 100, No.	d Biosynthe Vol 140, N	sis of Type 1 Co o. 1, January 19 opandable insuli	92.		
EXAMINER			DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.